Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Tislelizumab × Gastrointestinal × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4087 Pancreatic Neoplasms 2551 Carcinoma, Hepatocellular 2207 Stomach Neoplasms 2084 Colonic Neoplasms 1592 Rectal Neoplasms 1534 Esophageal Neoplasms 1219 Neoplasms 821 Liver Neoplasms 819 Breast Neoplasms 734 Neoplasm Metastasis 664 Carcinoma, Non-Small-Cell Lung 615 Cholangiocarcinoma 496 Lung Neoplasms 481 Ovarian Neoplasms 465 Esophageal Squamous Cell Carcinoma 464 Gastrointestinal Neoplasms 442 Melanoma 332 Prostatic Neoplasms 323 Biliary Tract Neoplasms 322 Head and Neck Neoplasms 265 Carcinoma, Renal Cell 247 Adenocarcinoma Of Esophagus 243 Uterine Cervical Neoplasms 242 Sarcoma 236 Squamous Cell Carcinoma of Head and Neck 234 Gastrointestinal Stromal Tumors 228 Endometrial Neoplasms 198 Gallbladder Neoplasms 197 Urinary Bladder Neoplasms 196

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡